CVD News Watch, June 12



worldnewsSome heart(y) news from the Baleares island of Mallorca where I am spending a week with my family. There’s nothing like jogging on the beach to pep up your health! You should try it!

CVD drug approval watch

Abbott, AstraZeneca seek cholesterol pill approval

Two pharma companies, Abbott Laboratories and AstraZeneca PLC have joined forces to apply for the approval of a combo-pill containing two cholesterol drugs TriLipix and Crestor to the US Food and Drug Administration (US FDA). Abbott is the maker of TriLipix which belong to a class of drugs called fibrates that raise the levels of “good” HDL cholesterol and lower the levels of triglycerides. Crestor, manufactured by AstraZeneca is a statin that lowers “bad” LDL cholesterol and raises HDL.

The combi drug would be a strong therapyA against dyslipidemia, a disorder characterized by elevated bad cholesterol and triglycerides, and low good cholesterol levels. If approved, the drug would be called Certriad

Crestor was London-based AstraZeneca’s third best-selling product last year with sales of $3.6 billion. Trilipix was launched last December. The drug had sales of $253 million in the first quarter, when combined with a related treatment called Tricor.

CVD drug and medical safety watch

Recalls and safety alerts from the US FDA

CVD clinical trial watch

Avandia on the RECORD: No “overall” CV risk increase, but trial remains controversial
The story about Avandia (rosiglitazone) is not yet over. The diabetes drug does not increase cardiovascular risk, according to the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) trial. However, sceptics remain sceptical and the drug remains controversial. Avandia is a product of GlaxoSmithKline. “Although our evidence is insufficient to rule out a small increased risk of myocardial infarction caused by rosiglitazone when compared with other glucose-lowering agents, rosiglitazone does not increase overall cardiovascular morbidity or mortality.”

Related Posts with Thumbnails
Print Friendly

Speak Your Mind

*


*

NOTE: The contents in this blog are for informational purposes only, and should not be construed as medical advice, diagnosis, treatment or a substitute for professional care. Always seek the advice of your physician or other qualified health professional before making changes to any existing treatment or program. Some of the information presented in this blog may already be out of date.
Read previous post:
News from the cancer side, June 12

News from the toxicologists Formaldehyde, pesticide increase cancer risk Two ongoing studies indicate that exposure to certain compounds increased the...

Close